In late July, the Food and Drug Administration (FDA) approved selective use of Praluent, the first of a new class of cholesterol-lowering drugs (PCSK9 inhibitors). A similar drug, Repatha, is expected to be approved this month. The reported results so
Read More...
Read the complete post at http://healthaffairs.org/blog/2015/08/25/a-rapid-learning-initiative-for-cholesterol-lowering-drugs/
Posted
Aug 25 2015, 10:19 AM
by
Health Affairs Blog
Filed under: Public Health, Quality, Population Health, Featured, Costs and Spending, Drugs and Medical Technology, regulation, FDA, genetic conditions, cholesterol-lowering drugs, rapid learning, Praluent, Repatha